Clearside to Shift Staff to Consultants, Halt R&D, as It Seeks Strategic Alternatives

Dow Jones

Jul 17, 2025

By Rob Curran

Clearside Biomedical will divert all employees to a consulting status and halt research-and-development, allowing the eye-care biotechnology firm to conserve cash during a search for a deal or other strategic alternatives.

The Alpharetta, Ga., biotech company hired investment bank Piper Sandler to help it identify a deal opportunity in licensing, merger-and-acquisitions, joint ventures or other strategic collaborations. The company said it was taking the unusual steps of suspending salaried positions and freezing internal R&D because of "unpredictable economic environment and challenging fundraising conditions in the biopharmaceutical industry."

As of Dec. 31, Clearside had 32 employees, according to a Securities and Exchange Commission filing.

President and Chief Executive George Lasezkay who will switch to a consulting capacity alongside the chief financial officer, the chief medical officer and the other employees, said he remained confident in the potential of the company's "SCS Microinjector" technology, which delivers medication behind the eye in a non-invasive fashion.

"We strongly believe that our proprietary suprachoroidal delivery platform provides an effective and reliable way to target challenging retinal diseases that need longer lasting treatments," said Lasezkay, in a statement.

Clearside shares fell 4% to 80 cents premarket.

Write to Rob Curran, rob.curran@dowjones.com

(END) Dow Jones Newswires

July 17, 2025 07:44 ET (11:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2552348925"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552348925\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552348925?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552348925","market":"hk","top_or_hot":-1,"title":"Clearside to Shift Staff to Consultants, Halt R&D, as It Seeks Strategic Alternatives","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CLSD\">Clearside Biomedical</a> will divert all employees to a consulting status and halt research-and-development, allowing the eye-care biotechnology firm to conserve cash during a search for a deal or other strategic alternatives. \n</p>\n<p>\n  The Alpharetta, Ga., biotech company hired investment bank Piper Sandler to help it identify a deal opportunity in licensing, merger-and-acquisitions, joint ventures or other strategic collaborations. The company said it was taking the unusual steps of suspending salaried positions and freezing internal R&amp;D because of \"unpredictable economic environment and challenging fundraising conditions in the biopharmaceutical industry.\" \n</p>\n<p>\n  As of Dec. 31, Clearside had 32 employees, according to a Securities and Exchange Commission filing. \n</p>\n<p>\n  President and Chief Executive George Lasezkay who will switch to a consulting capacity alongside the chief financial officer, the chief medical officer and the other employees, said he remained confident in the potential of the company's \"SCS Microinjector\" technology, which delivers medication behind the eye in a non-invasive fashion. \n</p>\n<p>\n  \"We strongly believe that our proprietary suprachoroidal delivery platform provides an effective and reliable way to target challenging retinal diseases that need longer lasting treatments,\" said Lasezkay, in a statement. \n</p>\n<p>\n  Clearside shares fell 4% to 80 cents premarket. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran, rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2025 07:44 ET (11:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearside to Shift Staff to Consultants, Halt R&D, as It Seeks Strategic Alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearside to Shift Staff to Consultants, Halt R&D, as It Seeks Strategic Alternatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-17 19:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CLSD\">Clearside Biomedical</a> will divert all employees to a consulting status and halt research-and-development, allowing the eye-care biotechnology firm to conserve cash during a search for a deal or other strategic alternatives. \n</p>\n<p>\n  The Alpharetta, Ga., biotech company hired investment bank Piper Sandler to help it identify a deal opportunity in licensing, merger-and-acquisitions, joint ventures or other strategic collaborations. The company said it was taking the unusual steps of suspending salaried positions and freezing internal R&amp;D because of \"unpredictable economic environment and challenging fundraising conditions in the biopharmaceutical industry.\" \n</p>\n<p>\n  As of Dec. 31, Clearside had 32 employees, according to a Securities and Exchange Commission filing. \n</p>\n<p>\n  President and Chief Executive George Lasezkay who will switch to a consulting capacity alongside the chief financial officer, the chief medical officer and the other employees, said he remained confident in the potential of the company's \"SCS Microinjector\" technology, which delivers medication behind the eye in a non-invasive fashion. \n</p>\n<p>\n  \"We strongly believe that our proprietary suprachoroidal delivery platform provides an effective and reliable way to target challenging retinal diseases that need longer lasting treatments,\" said Lasezkay, in a statement. \n</p>\n<p>\n  Clearside shares fell 4% to 80 cents premarket. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran, rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2025 07:44 ET (11:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLSD","symbol_name":"Clearside Biomedical Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2552348925","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552348925","pubTimestamp":1752752640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Clearside Biomedical will divert all employees to a consulting status and halt research-and-development, allowing the eye-care biotechnology firm to conserve cash during a search for a deal or other strategic alternatives.The Alpharetta, Ga., biotech company hired investment bank Piper Sandler to help it identify a deal opportunity in licensing, merger-and-acquisitions, joint ventures or other strategic collaborations. The company said it was taking the unusual steps of suspending salaried positions and freezing internal R&D because of \"unpredictable economic environment and challenging fundraising conditions in the biopharmaceutical industry.\". As of Dec. 31, Clearside had 32 employees, according to a Securities and Exchange Commission filing.President and Chief Executive George Lasezkay who will switch to a consulting capacity alongside the chief financial officer, the chief medical officer and the other employees, said he remained confident in the potential of the company's \"SCS Mic","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLSD":"Clearside Biomedical Inc.","BK4007":"制药"},"translate_title":"Clearside将员工转向顾问，停止研发，以寻求战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLSD":0.9},"content_text":"By Rob Curran \n\n\n \n\n\nClearside Biomedical will divert all employees to a consulting status and halt research-and-development, allowing the eye-care biotechnology firm to conserve cash during a search for a deal or other strategic alternatives. \n\n\n  The Alpharetta, Ga., biotech company hired investment bank Piper Sandler to help it identify a deal opportunity in licensing, merger-and-acquisitions, joint ventures or other strategic collaborations. The company said it was taking the unusual steps of suspending salaried positions and freezing internal R&D because of \"unpredictable economic environment and challenging fundraising conditions in the biopharmaceutical industry.\" \n\n\n  As of Dec. 31, Clearside had 32 employees, according to a Securities and Exchange Commission filing. \n\n\n  President and Chief Executive George Lasezkay who will switch to a consulting capacity alongside the chief financial officer, the chief medical officer and the other employees, said he remained confident in the potential of the company's \"SCS Microinjector\" technology, which delivers medication behind the eye in a non-invasive fashion. \n\n\n  \"We strongly believe that our proprietary suprachoroidal delivery platform provides an effective and reliable way to target challenging retinal diseases that need longer lasting treatments,\" said Lasezkay, in a statement. \n\n\n  Clearside shares fell 4% to 80 cents premarket. \n\n\n \n\n\n  Write to Rob Curran, rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2025 07:44 ET (11:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}